Yonsei University

Medicinal Bioconvergence Research Center

Ck Regeon Inc.

Gyoonhee Han

Sunghoon Kim

Jong Hyun Kim

Kang-Yell Choi

Chulho Lee

Jung Min Han

Sehee Choi

Jeong-Ha Hwang

Changmok Oh

The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.

Compound as mTOR inhibitor and use thereof

A composition for promoting longitudinal bone growth, according to the present invention, promotes the proliferation of the chondrocytes and the differentiation of the osteoblasts and has effects of simultaneously increasing longitudinal bone length and thickness (bone density), and thus has an advantage of being widely prescribable to various age groups, thereby being usable as a pharmaceutical composition for promoting the growth of longitudinal bone length and thickness. An indirubin derivative according to the present invention has prevention or treatment effects through oral administration. In addition, unlike conventional therapeutic agents, the pharmaceutical composition for preventing or treating bone diseases of the present invention is a stable compound, which is known to be substantially noncytotoxic to the human body, and is a material of which adverse effects have not been identified and has excellent treatment effects for bone diseases and osteogenesis imperfecta.

Pharmaceutical composition containing indirubin derivative as active ingredient

Growing community of inventors

Seoul, South Korea

Gyoonhee Han